| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Hajós, S E Gartside, T Shar. Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn-Schmiedeberg's archives of pharmacology. vol 351. issue 6. 1995-10-19. PMID:7675121. |
inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. |
1995-10-19 |
2023-08-12 |
rat |
| M Hajós, S E Gartside, T Shar. Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn-Schmiedeberg's archives of pharmacology. vol 351. issue 6. 1995-10-19. PMID:7675121. |
using in vivo extracellular electrophysiological recording techniques in the chloral hydrate anaesthetised rat, we have tested the effect of acute administration of the ssri, paroxetine, on 5-ht neuronal activity in the mrn and drn. |
1995-10-19 |
2023-08-12 |
rat |
| C Geretsegger, C H Stuppaeck, M Mair, T Platz, R Fartacek, M Hei. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology. vol 119. issue 3. 1995-10-18. PMID:7675961. |
paroxetine is a phenylpiperidine compound which is a selective serotonin reuptake inhibitor (ssri). |
1995-10-18 |
2023-08-12 |
Not clear |
| A T Harvey, M Burk. Comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. The American journal of emergency medicine. vol 13. issue 5. 1995-10-06. PMID:7662067. |
comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. |
1995-10-06 |
2023-08-12 |
Not clear |
| J M Gulley, C McNamara, T J Barbera, M C Ritz, F R Georg. Selective serotonin reuptake inhibitors: effects of chronic treatment on ethanol-reinforced behavior in mice. Alcohol (Fayetteville, N.Y.). vol 12. issue 3. 1995-09-18. PMID:7639947. |
in the present studies, c57bl/6j male mice were treated with one of three selective 5-ht reuptake inhibitors (ssris): fluoxetine, sertraline, or paroxetine. |
1995-09-18 |
2023-08-12 |
mouse |
| M R Briejer, G J Veen, L M Akkermans, R A Lefebvre, J A Schuurke. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon. The Journal of pharmacology and experimental therapeutics. vol 274. issue 2. 1995-09-08. PMID:7636723. |
the 5-ht relaxation-enhancing effects of cisapride were not mimicked by phentolamine (1 microm), nan-190 (0.03 microm), spiperone (1 microm), citalopram (0.3 microm), paroxetine (0.3 microm), pargyline (100 microm) or sdz 205-557 (0.3 microm). |
1995-09-08 |
2023-08-12 |
Not clear |
| W Boye. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. International clinical psychopharmacology. vol 10. issue 1. 1995-08-30. PMID:7622804. |
the serotonin reuptake inhibitors included paroxetine, fluvoxamine, zimelidine, and clomipramine. |
1995-08-30 |
2023-08-12 |
Not clear |
| P Baumann, B Rocha. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. International clinical psychopharmacology. vol 10 Suppl 1. 1995-08-30. PMID:7622807. |
the presently available selective serotonin reuptake inhibitors (ssris) citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline, despite their common mechanism of action, differ in their chemical structure, metabolism and pharmacokinetics. |
1995-08-30 |
2023-08-12 |
Not clear |
| S B Auerbach, J F Lundberg, S Hjort. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology. vol 34. issue 1. 1995-08-29. PMID:7623967. |
the largest decreases (about 60-70%) in 5-ht were produced by the selective 5-ht uptake inhibitors sertraline, paroxetine and citalopram. |
1995-08-29 |
2023-08-12 |
rat |
| J E Sprague, D E Nichol. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology. vol 118. issue 3. 1995-08-23. PMID:7542394. |
mdma alone produced a significant decrease in the number of 5-ht uptake sites, measured as a decrease in the bmax for binding of [3h]paroxetine, and in 5-ht and 5-hiaa levels in the striatum. |
1995-08-23 |
2023-08-12 |
rat |
| R B Rothman, M L Silverthorn, M H Baumann, C B Goodman, J L Cadet, D Matecka, K C Rice, F I Carroll, J B Wang, G R Uh. Studies of the biogenic amine transporters. VI. Characterization of a novel cocaine binding site, identified with [125I]RTI-55, in membranes prepared from whole rat brain minus caudate. The Journal of pharmacology and experimental therapeutics. vol 274. issue 1. 1995-08-18. PMID:7616423. |
paroxetine (50 nm) was used to block [125i]rti-55 binding to 5-ht transporter sites. |
1995-08-18 |
2023-08-12 |
rat |
| C G Fichtner, F L O'Connor, H C Yeoh, R C Arora, J W Crayto. Hypodensity of platelet serotonin uptake sites in posttraumatic stress disorder: associated clinical features. Life sciences. vol 57. issue 2. 1995-08-07. PMID:7603291. |
we have previously reported that binding to blood platelets of paroxetine, a selective serotonin (5-ht) reuptake inhibitor which binds to 5-ht uptake sites, is decreased in patients with posttraumatic stress disorder (ptsd). |
1995-08-07 |
2023-08-12 |
human |
| M Rafieian-Kopaei, A M Gray, P S Spencer, R D Sewel. Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning. European journal of pharmacology. vol 275. issue 2. 1995-08-03. PMID:7796854. |
it is suggested therefore that acute fluvoxamine may have decreased withdrawal aversion, probably through serotonin and also, in part, via an opioid-like mechanism whereas chronic paroxetine decreased withdrawal aversion by a serotonergic mechanism, but it is not clear whether opioid systems play any role in the action of paroxetine. |
1995-08-03 |
2023-08-12 |
rat |
| D R Gehlert, D A Schober, S K Hemrick-Luecke, J Krushinski, J J Howbert, D W Robertson, R W Fuller, D T Won. Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochemistry international. vol 26. issue 1. 1995-07-25. PMID:7787762. |
this analog was significantly less potent at the 5ht uptake site, as exhibited by a ki of 25 nm in the inhibition of [3h]paroxetine binding and a ki of 121 nm in [3h]5ht uptake. |
1995-07-25 |
2023-08-12 |
rat |
| E Eriksson, M A Hedberg, B Andersch, C Sundbla. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 12. issue 2. 1995-07-20. PMID:7779245. |
in order to elucidate whether all antidepressant drugs are equally effective in the treatment of pms or whether potent serotonin reuptake inhibition is a prerequisite for reducing premenstrual complaints, women suffering from severe pms were treated daily for three menstrual cycles with a selective serotonin reuptake inhibitor, paroxetine (n = 22), or with a selective noradrenaline reuptake inhibitor, maprotiline (n = 21); in addition, a placebo group was included (n = 22). |
1995-07-20 |
2023-08-12 |
human |
| E Eriksson, M A Hedberg, B Andersch, C Sundbla. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 12. issue 2. 1995-07-20. PMID:7779245. |
the clear-cut superiority of paroxetine over maprotiline indicates that not all antidepressant drugs are equally effective in the treatment of pms; rather, like panic disorder and obsessive compulsive disorder, but in contrast to depression, pms apparently responds better to serotonin reuptake inhibitors than to antidepressants with a noradrenergic profile. |
1995-07-20 |
2023-08-12 |
human |
| E Le Poul, L Lima, A M Laporte, C Even, E Doucet, C M Fattaccini, N Laaris, M Hamon, L Lanfume. [Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine]. L'Encephale. vol 21. issue 2. 1995-07-20. PMID:7781583. |
[central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine]. |
1995-07-20 |
2023-08-12 |
rat |
| E Le Poul, L Lima, A M Laporte, C Even, E Doucet, C M Fattaccini, N Laaris, M Hamon, L Lanfume. [Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine]. L'Encephale. vol 21. issue 2. 1995-07-20. PMID:7781583. |
these drugs, such as fluoxetine and paroxetine, exert their antidepressant activity by increasing 5-ht concentration in the synaptic cleft and thus enhancing serotonergic neurotransmission. |
1995-07-20 |
2023-08-12 |
rat |
| C Davidson, J A Stamfor. The effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus is potentiated by both 5-HT1A and 5-HT1B/D receptor antagonists. Neuroscience letters. vol 188. issue 1. 1995-07-20. PMID:7783975. |
the effect of paroxetine on 5-ht efflux in the rat dorsal raphe nucleus is potentiated by both 5-ht1a and 5-ht1b/d receptor antagonists. |
1995-07-20 |
2023-08-12 |
rat |
| C Davidson, J A Stamfor. The effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus is potentiated by both 5-HT1A and 5-HT1B/D receptor antagonists. Neuroscience letters. vol 188. issue 1. 1995-07-20. PMID:7783975. |
the selective serotonin re-uptake inhibitor (ssri) paroxetine (10(-7) m) increased 5-ht efflux to 147 +/- 6% of pre-drug values at maximum (mean +/- sem, n = 5) and the half-life of uptake to 443 +/- 38%. |
1995-07-20 |
2023-08-12 |
rat |